Pneumonia complicated by SARS-coV-2 infection in three patients with ankylosing spondylitis who are on anti-TNF therapy: Case-based review

The mortality rate for the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is increasing worldwide with each passing day. The risk factors for mortality include advanced age and comorbidities. It is still uncertain whether biological agents pose a risk for the progression...

Full description

Saved in:
Bibliographic Details
Main Authors: Serdar Kaymaz, Ugur Karasu, Veli Çobankara, Hakan Alkan, Firdevs Ulutas
Format: Article
Language:English
Published: SAGE Publishing 2020-01-01
Series:Indian Journal of Rheumatology
Subjects:
Online Access:http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=4;spage=341;epage=346;aulast=Kaymaz
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850283179937628160
author Serdar Kaymaz
Ugur Karasu
Veli Çobankara
Hakan Alkan
Firdevs Ulutas
author_facet Serdar Kaymaz
Ugur Karasu
Veli Çobankara
Hakan Alkan
Firdevs Ulutas
author_sort Serdar Kaymaz
collection DOAJ
description The mortality rate for the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is increasing worldwide with each passing day. The risk factors for mortality include advanced age and comorbidities. It is still uncertain whether biological agents pose a risk for the progression of SARS-CoV-2. Although there are studies suggesting the use of biological agents in the literature, there are also studies suggesting the discontinuation of biological agents during SARS-CoV-2. In this study, we aimed to determine whether anti-tumor necrosis factor (anti-TNF-α agents) therapy, which is one of the biological agents commonly used in rheumatology clinics, has an effect on the clinical course of SARS-CoV-2 infection, and to review the literature. We searched the MEDLINE/PubMed and SCOPUS databases until the date of August 15, 2020, using the following keywords: SARS-CoV-2 and anti-TNF-α agents. We reviewed abstracts and retrieved the relevant articles. We reported the clinical manifestation and disease course of SARS-CoV-2 pneumonia in three patients with ankylosing spondylitis who were receiving anti-TNF-α agents. All patients in our case series had a mild course similar to the most cases reported in the literature.
format Article
id doaj-art-78a27b82410b4358bb3e5ccdff337ee3
institution OA Journals
issn 0973-3698
0973-3701
language English
publishDate 2020-01-01
publisher SAGE Publishing
record_format Article
series Indian Journal of Rheumatology
spelling doaj-art-78a27b82410b4358bb3e5ccdff337ee32025-08-20T01:47:49ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012020-01-0115434134610.4103/injr.injr_221_20Pneumonia complicated by SARS-coV-2 infection in three patients with ankylosing spondylitis who are on anti-TNF therapy: Case-based reviewSerdar KaymazUgur KarasuVeli ÇobankaraHakan AlkanFirdevs UlutasThe mortality rate for the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is increasing worldwide with each passing day. The risk factors for mortality include advanced age and comorbidities. It is still uncertain whether biological agents pose a risk for the progression of SARS-CoV-2. Although there are studies suggesting the use of biological agents in the literature, there are also studies suggesting the discontinuation of biological agents during SARS-CoV-2. In this study, we aimed to determine whether anti-tumor necrosis factor (anti-TNF-α agents) therapy, which is one of the biological agents commonly used in rheumatology clinics, has an effect on the clinical course of SARS-CoV-2 infection, and to review the literature. We searched the MEDLINE/PubMed and SCOPUS databases until the date of August 15, 2020, using the following keywords: SARS-CoV-2 and anti-TNF-α agents. We reviewed abstracts and retrieved the relevant articles. We reported the clinical manifestation and disease course of SARS-CoV-2 pneumonia in three patients with ankylosing spondylitis who were receiving anti-TNF-α agents. All patients in our case series had a mild course similar to the most cases reported in the literature.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=4;spage=341;epage=346;aulast=Kaymazankylosing spondylitisanti-tumor necrosis factorcoronavirus disease 2019severe acute respiratory syndrome coronavirus 2
spellingShingle Serdar Kaymaz
Ugur Karasu
Veli Çobankara
Hakan Alkan
Firdevs Ulutas
Pneumonia complicated by SARS-coV-2 infection in three patients with ankylosing spondylitis who are on anti-TNF therapy: Case-based review
Indian Journal of Rheumatology
ankylosing spondylitis
anti-tumor necrosis factor
coronavirus disease 2019
severe acute respiratory syndrome coronavirus 2
title Pneumonia complicated by SARS-coV-2 infection in three patients with ankylosing spondylitis who are on anti-TNF therapy: Case-based review
title_full Pneumonia complicated by SARS-coV-2 infection in three patients with ankylosing spondylitis who are on anti-TNF therapy: Case-based review
title_fullStr Pneumonia complicated by SARS-coV-2 infection in three patients with ankylosing spondylitis who are on anti-TNF therapy: Case-based review
title_full_unstemmed Pneumonia complicated by SARS-coV-2 infection in three patients with ankylosing spondylitis who are on anti-TNF therapy: Case-based review
title_short Pneumonia complicated by SARS-coV-2 infection in three patients with ankylosing spondylitis who are on anti-TNF therapy: Case-based review
title_sort pneumonia complicated by sars cov 2 infection in three patients with ankylosing spondylitis who are on anti tnf therapy case based review
topic ankylosing spondylitis
anti-tumor necrosis factor
coronavirus disease 2019
severe acute respiratory syndrome coronavirus 2
url http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2020;volume=15;issue=4;spage=341;epage=346;aulast=Kaymaz
work_keys_str_mv AT serdarkaymaz pneumoniacomplicatedbysarscov2infectioninthreepatientswithankylosingspondylitiswhoareonantitnftherapycasebasedreview
AT ugurkarasu pneumoniacomplicatedbysarscov2infectioninthreepatientswithankylosingspondylitiswhoareonantitnftherapycasebasedreview
AT velicobankara pneumoniacomplicatedbysarscov2infectioninthreepatientswithankylosingspondylitiswhoareonantitnftherapycasebasedreview
AT hakanalkan pneumoniacomplicatedbysarscov2infectioninthreepatientswithankylosingspondylitiswhoareonantitnftherapycasebasedreview
AT firdevsulutas pneumoniacomplicatedbysarscov2infectioninthreepatientswithankylosingspondylitiswhoareonantitnftherapycasebasedreview